## Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

- 1. (Currently amended) A method of treating hot flashes in a patient comprising:
- providing a tachykinin receptor antagonist selected from the group of <a href="neurokinin-2">neurokinin-2</a> (NK<sub>2</sub>) receptor antagonists and <a href="neurokinin-3">neurokinin-3</a> (NK<sub>3</sub>) receptor antagonist; and administering the tachykinin receptor antagonist to a patient experiencing hot flashes under conditions effective to treat the hot flashes.
- 2. (Original) The method according to claim 1, wherein the tachykinin receptor antagonist is a NK<sub>2</sub> receptor antagonist.
  - 3. (Cancelled)
- 4. (Original) The method according to claim 1, wherein the tachykinin receptor antagonist is a NK<sub>3</sub> receptor antagonist.
  - 5. (Cancelled)
- 6. (Original) The method according to claim 1, wherein the tachykinin receptor antagonist comprises a combination of tachykinin receptor antagonists.
- 7. (Currently amended) The method according to claim 6, wherein the combination of tachykinin receptor antagonists comprises a second tachykinin receptor antagonist selected from the group of <a href="mailto:neurokinin-1">neurokinin-1</a> (NK<sub>1</sub>) receptor antagonists, NK<sub>2</sub> receptor antagonists, and NK<sub>3</sub> receptor antagonists.
- 8. (Original) The method according to claim 1, wherein the tachykinin receptor antagonist is administered in an amount of about 10 to about 5000 mg per day.
- 9. (Original) The method according to claim 1, wherein the patient is a female patient.

- 10. (Original) The method according to claim 9, wherein the female patient is postmenopausal.
- 11. (Original) The method according to claim 10, wherein menopause is drug induced, surgically induced, or naturally-occurring.
- 12. (Original) The method according to claim 11, wherein menopause is drug induced.
- 13. (Original) The method according to claim 12, wherein the drug is an antiestrogen compound.
- 14. (Original) The method according to claim 13, wherein the anti-estrogen compound is tamoxifen.
- 15. (Original) The method according to claim 1, wherein the patient is a male patient.
- 16. (Original) The method according to claim 15, wherein the male patient experiences drug induced hot flashes.
- 17. (Original) The method according to claim 16, wherein the drug is an antiandrogen compound.
- 18. (Original) The method according to claim 17, wherein the anti-androgen compound is leuprolide acetate.
- 19. (Original) The method according to claim 1, wherein said administration is carried out orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by implantation, by intracavitary or intravesical instillation, intraocularly, intraarterially, intralesionally, transdermally, or by application to mucous membranes.

- 20. (Original) The method according to claim 1, wherein the tachykinin receptor antagonist is present in a pharmaceutical composition comprising the tachykinin receptor antagonist and a pharmaceutically-acceptable carrier.
- 21. (Original) The method according to claim 20, wherein the pharmaceutical composition is in a liquid or solid dosage form.
- 22. (New) A method of treating hot flashes in a patient comprising:

  providing a neurokinin-2 (NK<sub>2</sub>) receptor antagonist selected from the
  group consisting of (S)-N-Methyl-N(4-(4-acetylamino-4-phenylpiperidino)-2-(3,4dichlorophenyl)butyl)benzamide (saredutant), cyclo(Met-Asp-Trp-Phe-Dap-Leu)cyclo(2 beta-5
  beta) (MEN 10627), and combinations thereof; and

administering the  $NK_2$  receptor antagonist to a patient experiencing hot flashes under conditions effective to treat the hot flashes.

23. (New) A method of treating hot flashes in a patient comprising: providing a neurokinin-3 (NK<sub>3</sub>) receptor antagonist selected from the group consisting of (S)-(-)-N-(α-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (talnetant), N-(1-(3-((R)-1-Benzoyl-3-(3,4-dichlorophenyl)-3-piperidyl)propyl)-4-phenyl-4-piperidyl)-N-methylacetamide (osanetant), and combinations thereof; and

administering the NK<sub>3</sub> receptor antagonist to a patient experiencing hot flashes under conditions effective to treat the hot flashes.